Pasithea Therapeutics (KTTA) Interest & Investment Income (2023 - 2026)

Pasithea Therapeutics has reported Interest & Investment Income for 4 years, with the latest figure at $450338.0 in Q1 2026.

• Quarterly Interest & Investment Income rose 853.2% year-over-year to $450338.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $730286.0 (up 130.22% YoY) and the FY2025 annual result came in at $327193.0, down 22.68% from the prior year.
• Interest & Investment Income climbed to $450338.0 in Q1 2026 per KTTA's latest filing, from $182128.0 in the prior quarter.
• Over five years, Interest & Investment Income peaked at $450338.0 in Q1 2026 and troughed at $43396.0 in Q3 2025.
• A 4-year average of $136843.6 and a median of $114407.0 in 2024 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2025 and 2026: Interest & Investment Income slumped 69.16% in 2025, then soared 853.2% in 2026.
• Over 4 years, Interest & Investment Income stood at $172825.0 in 2023, then plunged by 53.43% to $80483.0 in 2024, then jumped by 126.29% to $182128.0 in 2025, then surged by 147.26% to $450338.0 in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $450338.0, $182128.0, and $43396.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.